Correlation Between Marinus Pharmaceuticals and Equillium

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Marinus Pharmaceuticals and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Marinus Pharmaceuticals and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Marinus Pharmaceuticals and Equillium, you can compare the effects of market volatilities on Marinus Pharmaceuticals and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Marinus Pharmaceuticals with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Marinus Pharmaceuticals and Equillium.

Diversification Opportunities for Marinus Pharmaceuticals and Equillium

0.25
  Correlation Coefficient

Modest diversification

The 3 months correlation between Marinus and Equillium is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Marinus Pharmaceuticals and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Marinus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Marinus Pharmaceuticals are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Marinus Pharmaceuticals i.e., Marinus Pharmaceuticals and Equillium go up and down completely randomly.

Pair Corralation between Marinus Pharmaceuticals and Equillium

Given the investment horizon of 90 days Marinus Pharmaceuticals is expected to under-perform the Equillium. In addition to that, Marinus Pharmaceuticals is 1.07 times more volatile than Equillium. It trades about -0.01 of its total potential returns per unit of risk. Equillium is currently generating about 0.03 per unit of volatility. If you would invest  90.00  in Equillium on September 12, 2024 and sell it today you would lose (20.00) from holding Equillium or give up 22.22% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Marinus Pharmaceuticals  vs.  Equillium

 Performance 
       Timeline  
Marinus Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Marinus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Equillium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Equillium is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Marinus Pharmaceuticals and Equillium Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Marinus Pharmaceuticals and Equillium

The main advantage of trading using opposite Marinus Pharmaceuticals and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Marinus Pharmaceuticals position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.
The idea behind Marinus Pharmaceuticals and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets